Tag: Hepatitis d

Chronic hepatitis D virus (HDV) infection, which only occurs in people with hepatitis B, is a rare but serious condition for which the injectable drug Hepcludex (bulevirtide) is prescribed. This must be distinguished from the oral dietary supplement, the **Hepclude Tablet**, which is used for general liver health support and detoxification. This guide clarifies the important differences to help you determine which product is being discussed.

Approved in the European Union in 2020, Hepcludex (bulevirtide) represents a major advancement in the treatment of chronic hepatitis D. This innovative antiviral operates through a highly specific viral entry inhibition, providing a new targeted approach to controlling viral spread. Understanding **what is the mechanism of action of Hepcludex?** reveals its precise strategy for combating chronic hepatitis D.

Hepatitis D is the most severe form of viral hepatitis, and for decades, treatment options were severely limited. However, the approval of Hepcludex has introduced a new class of medication, known as an entry inhibitor, that effectively blocks both the hepatitis B and delta viruses from infecting healthy liver cells.